Ipsen media releases

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 20 Press Releases

Show

Sort

28 April 2025

28 April 2025

Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis

04 May 2022

04 May 2022

Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer

20 October 2021

20 October 2021

Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma

16 March 2021

16 March 2021

Health Canada Approves INCRELEX®, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents

04 May 2020

04 May 2020

Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program